Cell Therapies Pty Ltd, a leading provider of cell and gene therapy products in the Asia Pacific region, is delighted to announce the appointment of Dr Bev Menner as the company’s new Chief Executive Officer.
Dr Menner has over 20 years’ experience across the Australian and North American bio/healthcare sector, having commenced her career with Postdoctoral roles in cancer research at Memorial Sloan Kettering Cancer Centre and the Peter MacCallum Cancer Centre, before moving to commercial roles in research project management and more recently in leading alliance management and global partnerships in larger pharmaceutical companies. She will be known to many because of her central role in leading the partnership between CSL and AstraZeneca for COVID vaccines production for Australia.
Cell Therapies Chair Matt O’Keefe said the appointment was very exciting for Cell Therapies and its majority shareholder, the Peter MacCallum Cancer Centre. “We really look forward to Bev leading our high-performing team into an exciting phase of its growth and development,” he said.
Dr Menner will commence as Cell Therapies’ Chief Executive Officer on Monday 2nd October 2023, succeeding A/Prof Dominic Wall, Chief Scientific Officer and interim CEO. The Cell Therapies Pty Ltd Board of Directors would like to take this opportunity to thank Dominic for his leadership during the transition period.
<Ends>.
